CD38 and interleukin 6 gene polymorphism in egyptians with diffuse large B-cell lymphoma (DLBCL)

Area of Science:

• Genetics
• Oncology
• Immunology

Background:

• Non-Hodgkin's lymphoma (NHL) pathogenesis involves genetic variations.
• Diffuse large B cell lymphoma (DLBCL) is a major NHL subtype.
• Understanding gene polymorphism is crucial for disease susceptibility studies.

Purpose of the Study:

• Investigate the impact of CD38 (184C/G) and IL-6 (-174 G/C) gene polymorphism on DLBCL susceptibility in Egyptians.
• This study is the first to examine CD38 polymorphism in NHL.
• Assess serum IL-6 levels in relation to DLBCL.

Main Methods:

• Pilot study involving 100 Egyptian DLBCL patients and 119 controls.
• Genotyping using Restriction Fragment Length Polymorphism-Polymerase Chain Reaction (RFLP-PCR) for CD38 and Mutagenically Separated PCR (MS-PCR) for IL-6.
• Serum IL-6 levels measured by Enzyme-linked Immunosorbent Assay (ELISA).

Main Results:

• CD38 (184C/G) genotype significantly increased in NHL patients (p < 0.01).
• GG genotype of CD38 was significantly higher in controls (p < 0.05).
• Significantly elevated serum IL-6 levels (p < 0.05) correlated with DLBCL (r=0.17, p < 0.05).

Conclusions:

• CD38 gene polymorphism plays a role in DLBCL development.
• The CD38 (184) CG genotype may contribute to DLBCL susceptibility in Egyptians.
• Further research with larger populations is needed to validate these findings.